The Brain-Computer Interface (BCI) sector is a potential high-risk, high-reward play. Below we take a look at the current state of the medical market grabbing headlines, what is BCI, the risks inherent and the market leaders.
A Snapshot of the Current State of the US Medical Sector
The medical industry in America has been pummeled in 2025 by multiple attacks from the administration; first of which are the vaccine skeptics, where vaccines are a major revenue line of the pharmaceutical industry. The second reason the pharmaceutical industry is undergoing distress is the forced lowering of drug prices that the administration is pushing for. The third is the active discouragement of the taking of certain medicines and the fourth is the cracking down on direct-to-consumer (DTC) drug ads.
On the flipside, one great boon for the industry has been Novo Nordisk and Eli Lilly’s ‘thinning’ drugs. Therefore, certain sectors of the US’ pharmaceutical and medical industry are currently undergoing changes of ups and downs (mostly downs) but one industry which is potentially explosive is the extremely speculative brain-computer interface sector.
What are Brain-Computer Interface Companies?
The Brain-Computer Interface industry is (almost painfully put) simply how the human mind can interact with machines. Already, multiple breakthroughs have been achieved in this industry, including; high-bandwidth data without deep implants, restoring speech, voice synthesis for paralysed individuals using AI to decode brain signals into text/audio, decoding complex actions like wheelchair control and more.
A lot of people will have their own personal – and often visceral – thoughts on transhumanism; however, it’s worth looking into the BCI industry, in case it takes off in a big way.
There are certain heavy-hitters in this space, obviously the foremost being Elon Musk’s Neuralink but also Jeff Bezos and Bill Gates have made a movement with the BCI venture Synchron. Most recently, OpenAI has invested in Merge Labs, with the announcement coming in Thursday last week.
BCI is a highly speculative play and the fact is one or two other sectors have to jump substantially first, the first of which is the Augmented Reality (AR) trade. Once retail begins to incorporate AR glasses much more – with 2026 being a big year for the product type with multiple launches scheduled – it opens the pathway for other human-machine interactions.
A High-Risk Prone Sector
BCI is an interesting sector, with most companies in the sector trading on the market at record lows. As the quantum computing industry has shown, you only need to prove a few things correct before an industry can be worth tens of billions of dollars in the current macro environment.
The downside of this space is that there are a plethora of medical startup companies in it that are pure plays and being able to spot one that is not prone to permanent loss – read: bankruptcy – is tricky. As most experienced investors are well aware, medical startups are some of the riskiest and most prone to being renegaded into the halls of penny stocks (indeed, a lot of neural/BCI companies are now trading at penny stocks levels). It is also worth pointing out that even if an industry is going to go up quickly and grab the attention of the market, that alone doesn’t detract from the potential for permanent loss and the trend can start too late for some. This was seen in the quantum trade when a few quantum companies went into very difficult trading periods – notably Zapata Computing and Nordic Quantum Computing Group in Q4 2024 – one or two months before IonQ and others began their meteoric rises. Indeed, in Q4 2024, even D-Wave Quantum and Rigetti Computing faced delisting.
On one hand, the larger number of pure play names that are in the BCI space means that it is possible to somewhat diversify; on the other it also means it is harder to pick winners and more likely to suffer permanent loss on more holdings. So, who are the leaders of this nascent industry?
Brain-Computer Interface Stock Leaders
Weirdly, one of the safest ways to have significant upside-exposure to the BCI industry is through the struggling-to-ever-achieve-profit firm Snapchat. Snapchat bought the French BCI startup NextMind in 2022. With Snap one of the companies slated to release their AR glasses product in 2026, and the stock at near-record lows, it might have more of an upside than Meta – which had bought the neural company CTRL-Labs in 2019, 6 years before launching their AR glasses. In addition, NextMind appears to have been a more advanced BCI company than CTRL-Labs at their respective times of acquisition.
Nevertheless, neither Snapchat nor Meta are pure play publicly traded BCI firms. For that, one would have to pick out firms such as; ClearPoint Neuro, NeuroPace, NeuroOne Medical Technologies, Neuronetics, Minerva Neurosciences, Integra LifeSciences and NeuroSense Therapeutics.
Some of these firms even have a relatively promising market structure, the principal standout being ClearPoint Neuro, which, as the most well-capitalised pure play brain-computer interface firm on the market, also happens to be trading in the potential beginning of a parabolic rise.
Integra LifeSciences – another well-capitalised BCI play – appears to have bottomed out and formed a diamond formation at the end of a ~6-year long downtrend.
Meanwhile, smaller player Neuronetics has healthy peaks and troughs.
Price Discoveries Disclosure: Not financial advice. No guidance is provided for any particular investor, asset prices can fall as well as rise. Price Discoveries is not a licensed securities dealer, broker, investment bank or advisor.
Price Discoveries 